Takhzyro (lanadelumab)

lanadelumab · Regeneron Pharmaceuticals, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Takhzyro (lanadelumab), covering 2024-06-17 to 2024-06-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor [Phase 3]

See pricing